Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist - PubMed (original) (raw)

Randomized Controlled Trial

. 2009 Dec;70(12):1662-6.

doi: 10.4088/JCP.08m04659. Epub 2009 Sep 8.

Affiliations

Randomized Controlled Trial

Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist

Rodrigo Machado-Vieira et al. J Clin Psychiatry. 2009 Dec.

Abstract

Objective: A model has been proposed to explain the pathophysiology of mood disorders based on decreased neurotrophin levels during mood episodes; treatment with antidepressants and mood stabilizers is associated with clinical improvement. This study investigated whether changes in brain-derived neurotrophic factor (BDNF) levels are associated with the initial antidepressant effects of ketamine, a high-affinity N-methyl-D-aspartate (NMDA) antagonist.

Method: Twenty-three subjects aged 18 to 65 years with DSM-IV major depressive disorder (treatment resistant) participated in this study, which was conducted between October 2006 and May 2008. The subjects were given an open-label intravenous infusion of ketamine hydrochloride (0.5 mg/kg) and rated using various depression scales at baseline and at 40, 80, 120, and 230 minutes postinfusion. The primary outcome measure was the Montgomery-Asberg Depression Rating Scale score. BDNF levels were obtained at the same time points as depression rating scale scores.

Results: Despite a significant (P <. 001) improvement in MADRS scores after subjects received ketamine treatment, no changes in BDNF levels were observed in subjects after they received ketamine compared to baseline. Also, no association was found between antidepressant response and BDNF levels.

Conclusions: This study demonstrates that ketamine's rapid initial antidepressant effects are not mediated by BDNF. Further studies are necessary to shed light on the neurobiological basis of these effects.

Trial registration: clinicaltrials.gov Identifiers: NCT00024635 and NCT00088699.

Copyright 2009 Physicians Postgraduate Press, Inc.

PubMed Disclaimer

Figures

Figure 1

Figure 1

BDNF Values and MADRS Scores Over 230 Minutes in Subjects With Major Depressive Disorder (treatment resistent) who Did and Did Not Respond to ketamine (N=23) *p<.05, ***p<.001 after Bonferroni correction. Abbreviations: BDNF = brain derived neurotrophic factor, MADRS = Montgomery-Asberg Depression Rating Scale.

Similar articles

Cited by

References

    1. Zarate CA, Jr, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry. 2006;59(11):1006–1020. doi: 10.1016/j.biopsych.2005.10.021. - DOI - PubMed
    1. Drevets WC, Price JL, Simpson JR, Jr, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997;386(6627):824–827. doi: 10.1038/386824a0. - DOI - PubMed
    1. Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med. 2004;5(1):11–25. doi: 10.1385/NMM:5:1:011. - DOI - PubMed
    1. Altar CA. Neurotrophins and depression. Trends Pharmacol Sci. 1999;20(2):59–61. doi: 10.1016/S0165-6147(99)01309-7. - DOI - PubMed
    1. Karege F, Perret G, Bondolfi G, et al. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002;109(2):143–148. doi: 10.1016/S0165-1781(02)00005-7. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources